Scinai Immunotherapeutics shares are trading higher after the company announced results in a preclinical study of Scinai's anti‑interleukin 17 NanoAbs as a treatment for plaque psoriasis.
Portfolio Pulse from Benzinga Newsdesk
Scinai Immunotherapeutics announced positive results in a preclinical study of its anti‑interleukin 17 NanoAbs treatment for plaque psoriasis, leading to a rise in its share prices.
September 13, 2023 | 8:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Scinai Immunotherapeutics' stock is trading higher after the company announced positive results in a preclinical study of its plaque psoriasis treatment.
The positive results from the preclinical study of Scinai's treatment for plaque psoriasis have increased investor confidence, leading to a rise in the company's stock price. This news is highly relevant and important for investors as it indicates potential future revenue from the new treatment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100